



IFW

Attorney Docket No.: 6550.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Vedso et al.

Serial No.: 10/697,226

Group Art Unit: 1621

Filed: October 30, 2003

Examiner: To be assigned

For: Halo Sulfonyl Aryl Boronates

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:


1. Supplemental Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on **May 25, 2004**

Gwendolyn Wardell-O'Neal  
(name of person mailing paper)

  
(signature of person mailing paper)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Vedso et al.

Application No.: 10/697,226

Group Art Unit: To be assigned

Filed: October 30, 2003

Examiner: To be assigned

For: Halo Sulfonyl Aryl Boronates

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. WO 02/32884 A2
2. Dicesare et al., STN Database accession No. 768624 Zcaplus [online], Abstract & Chemical Communications, Vol. 19, pp. 2022-2023 (2001)
3. International Search Report mailed March 19, 2004

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Date: May 25, 2004

Respectfully submitted,



Rosemarie R. Wilk-Orescan, Reg. No. 45,220

Novo Nordisk Pharmaceuticals, Inc.

100 College Road West

Princeton, NJ 08540

(609) 987-5800

23650

PATENT TRADEMARK OFFICE

FORM PTO 449  
(Rev. 2-32)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6550.200-US

Serial No. 10/697,226

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Applicant Vedso et al.

Filing Date October 30, 2003

Group 1621

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 02/32884 A2	04/25/02	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Dicesare et al., STN Database accession No. 768624 Zcaplus [online], Abstract &
		Chemical Communications, Vol. 19, pp. 2022-2023 (2001)
		International Search Report mailed March 19, 2004

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.